« Back
Home /
Giredestrant (tartrate)

Giredestrant (tartrate)

Item no.	DCC-DC60185-1g
Manufacturer	DCChemicals
CASRN	2407529-33-1
Amount	1 g
Quantity options	100 mg 1 g 250 mg
Category	Reagents & Chemicals Molecules
Type	Chemicals
Applications	with potential antineoplastic activity. Upon oral administration, Giredestrant, also known as GDC-9545 and RG6171, is a SERD. GDC-9545 is an orally available selective estrogen receptor degrader/downregulator (SERD), SERD GDC-9545 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation.
Specific against	other
Smiles	FC(C([H])([H])O[H])(C([H])([H])N1[C@]([H])(C([H])([H])[H])C([H])([H])C2C3=C([H])C([H])=C([H])C([H])=C3N([H])C=2[C@@]1([H])C1C(=C([H])C(=C([H])C=1F)N([H])C1([H])C([H])([H])N(C([H])([H])C([H])([H])C([H])([H])F)C1([H])[H])F)F.O([H])[C@@]([H])(C(=O)O[H])[C@]([H])(C(=O)O[H])O[H]
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Available
Manufacturer - Applications	Giredestrant, also known as GDC-9545 and RG6171, is a SERD. GDC-9545 is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD GDC-9545 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation.
Molecular Weight	672, 65

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 g

available

Delivery expected until 11/13/2025

Express Delivery: Save 2 days

Compare

Add to wishlist

Get an offer